Your request to link to rcsb for Cathepsin K

---

• 1MEM: crystal structure of cathepsin k complexed with a potent vinyl sulfone inhibitor (10.1038/NSB0297-105 )
• 1NL6: crystal structure of the cysteine protease human cathepsin k in complex with a covalent azepanone inhibitor (10.1021/JM000481X )
• 1NLJ: crystal structure of the cysteine protease human cathepsin k in complex with a covalent azepanone inhibitor (10.1021/JM000481X )
• 1Q6K: cathepsin k complexed with t-butyl(1s)-1-cyclohexyl-2- oxoethylcarbamate (10.1016/J.BMCL.2003.09.088 )
• 1SNK: cathepsin k complexed with carbamate derivatized norleucine aldehyde (10.1016/J.BMCL.2004.04.084 )
• 1TU6: cathepsin k complexed with a ketoamide inhibitor (10.1016/J.BMCL.2004.07.031 )
• 1U9V: crystal structure of the cysteine protease human cathepsin k in complex with the covalent inhibitor nvp-abe854 (10.1021/JM0493111 )
• 1U9W: crystal structure of the cysteine protease human cathepsin k in complex with the covalent inhibitor nvp-abi491 (10.1021/JM0493111 )
• 1U9X: crystal structure of the cysteine protease human cathepsin k in complex with the covalent inhibitor nvp-abj688 (10.1021/JM0493111 )
• 1VSN: crystal structure of a potent small molecule inhibitor bound to cathepsin k (10.1016/J.BMCL.2005.12.071 )
• 1YK7: cathepsin k complexed with a cyanopyrrolidine inhibitor (10.1016/J.BMCL.2005.02.033 )
• 1YK8: cathepsin k complexed with a cyanamide-based inhibitor (10.1016/J.BMCL.2005.04.032 )
• 1YT7: cathepsin k complexed with a constrained ketoamide inhibitor (10.1016/J.BMCL.2005.05.062 )
• 2ATO: crystal structure of human cathepsin k in complex with myocrisin (10.1515/BC.2007.037 )
• 2AUX: cathepsin k complexed with a semicarbazone inhibitor (10.1016/J.BMCL.2005.10.108 )
• 2AUZ: cathepsin k complexed with a semicarbazone inhibitor (10.1016/J.BMCL.2005.10.108 )
• 2BDL: cathepsin k complexed with a pyrrolidine ketoamide-based inhibitor (10.1016/J.BMCL.2005.11.101 )
• 2F7D: a mutant rabbit cathepsin k with a nitrile inhibitor (10.1021/JM051059P )
• 2FTD: crystal structure of cathepsin k complexed with 7-methyl- substituted azepan-3-one compound (10.1021/JM050915U )
• 2R6N: crystal structure of a pyrrolopyrimidine inhibitor in complex with human cathepsin k (10.1016/J.BMCL.2007.09.047 )
• 3C9E: crystal structure of the cathepsin k : chondroitin sulfate complex. (10.1016/J.JMB.2008.07.038 )
• 3H7D: the crystal structure of the cathepsin k variant m5 in complex with chondroitin-4-sulfate (10.1074/JBC.M110.126706 )
• 3KW9: x-ray structure of cathepsin k covalently bound to a triazine ligand (10.1016/J.BMCL.2010.01.100 )
• 3KWB: structure of catk covalently bound to a dioxo-triazine inhibitor (10.1016/J.BMCL.2010.01.116 )
• 3KWZ: cathepsin k in complex with a non-selective 2-cyano-pyrimidine inhibitor (10.1016/J.BMCL.2010.01.100 )
• 3KX1: cathepsin k in complex with a selective 2-cyano-pyrimidine inhibitor (10.1016/J.BMCL.2010.01.100 )
• 3O0U: cathepsin k covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over herg (10.1016/J.BMCL.2010.08.101 )
• 3O1G: cathepsin k covalently bound to a 2-cyano pyrimidine inhibitor with a benzyl p3 group. (10.1016/J.BMCL.2010.08.101 )
• 3OVZ: cathepsin k in complex with a covalent inhibitor with a ketoamide warhead (10.1016/J.BMCL.2010.10.012 )
• 4DMX: cathepsin k inhibitor (10.1021/JM3007257 )
• 4DMY: cathepsin k inhibitor (10.1021/JM3007257 )
• 4N79: structure of cathepsin k-dermatan sulfate complex (10.1073/PNAS.1414126111 )
• 4N8W: cathepsin k - chondroitin sulfate complex (10.1073/PNAS.1414126111 )
• 4X6H: development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. (10.1021/ACS.JMEDCHEM.5B00746 )
• 4X6I: development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. (10.1021/ACS.JMEDCHEM.5B00746 )
• 4X6J: development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. (10.1021/ACS.JMEDCHEM.5B00746 )
• 4YV8: crystal structure of cathepsin k bound to the covalent inhibitor lichostatinal (10.1021/ACS.JNATPROD.6B00215 )
• 4YVA: cathepsin k co-crystallized with actinomycetes extract (10.1021/ACS.JNATPROD.6B00215 )
• 5J94: human cathepsin k mutant c25s in complex with the allosteric effector nsc13345 (10.1038/NCOMMS4287 )
• 5JA7: human cathepsin k mutant c25s in complex with the allosteric effector nsc94914 (10.1002/1873-3468.12495 )
• 5JH3: human cathepsin k mutant c25s (10.1002/1873-3468.12495 )
• 5T6U: crystal structure of mouse cathepsin k at 2.9 angstroms resolution. (10.1042/BCJ20160985 )
• 5TDI: crystal structure of cathepsin k with a covalently-linked inhibitor at 1.4 angstrom resolution. 01-feb-17 5tdi 1 title (10.1042/BCJ20160985 )
• 5TUN: crystal structure of uninhibited human cathepsin k at 1.62 angstrom resolution 01-feb-17 5tun 1 title (10.1042/BCJ20160985 )
• 5Z5O: structure of pycnonodysostosis disease related i249t mutant of human cathepsin k (10.1111/FEBS.14655 )
• 6ASH: crystal structure of human cathepsin k with a non-active site inhibitor at 1.42 angstrom resolution
• 6BKI: crystal structure of t101a variant mouse cathepsin k at 2.94 angstrom resolution.
• 6HGY: crystal structure of cathepsin k with n-desmethyl thalassospiramide c (10.1021/ACS.ORGLETT.8B03821 )
• 6PXF: structure of human cathepsin k with an ectosteric inhibitor at 1.85 angstrom resolution
• 6QBS: the alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin k (10.1021/JACS.8B11027 )
• 6QL8: cathepsin-k in complex with miv-711
• 6QLM: cathepsin-k in complex with miv-701
• 6QLW: cathepsin-k in complex with miv-710
• 6QLX: cathepsin-k in complex with fluoro-oxa-azabicyclo[3.3.0]octanyl containing inhibitor
• 6QM0: cathepsin-k in complex with amino-oxaazabicyclo[3.3.0]octanyl containing inhibitor
• 7NXM: structure of human cathepsin k in complex with the selective activity- based probe gu3416
• 7PCK: crystal structure of wild type human procathepsin k
• 7QBL: structure of cathepsin k in complex with the 3-cyano-3-aza-beta-amino acid inhibitor gu2602 (10.1080/14756366.2021.2024527 )
• 7QBM: structure of the activation intermediate of cathepsin k in complex with the 3-cyano-3-aza-beta-amino acid inhibitor gu2602 (10.1080/14756366.2021.2024527 )
• 7QBN: structure of cathepsin k in complex with the azadipeptide nitrile inhibitor gu1303 (10.1080/14756366.2021.2024527 )
• 7QBO: structure of the activation intermediate of cathepsin k in complex with the azadipeptide nitrile inhibitor gu1303 (10.1080/14756366.2021.2024527 )